

## Evaluation of *invitro* anti-oxidant and anti-epileptic activities of *Calliandra haematocephala* using zebra fish model

A Krishnaveni<sup>1\*</sup>, Manjula B<sup>2</sup>, Sandhiya S<sup>2</sup>, Vaishnavi G<sup>2</sup>, kavin T<sup>3</sup>, Padmini M<sup>3</sup>, Selvakumar S<sup>1</sup>

<sup>1</sup> Assistant professor, Department of Pharmacy, College of Pharmacy, Madurai Medical College, Madurai, Affiliated to Tamil Nadu Dr. MGR Medical University, Chennai, Tamil Nadu, India

<sup>2</sup> Department of Pharmacy, College of Pharmacy, Madurai Medical College, Madurai, Affiliated to Tamil Nadu Dr. MGR Medical University, Chennai, Tamil Nadu, India

<sup>3</sup> Veterinary Assistant Surgeon, Department of Pharmacy, College of Pharmacy, Madurai Medical College, Madurai, Affiliated to Tamil Nadu Dr. MGR Medical University, Chennai, Tamil Nadu, India

### Abstract

**Background:** *Calliandra haematocephala* Hassk commonly known as the red powder puff, is a small ornamental shrub belongs to Fabaceae. It is widely distributed in tropical and subtropical regions, including India, Southeast Asia, Africa, and Central America. Though popularly cultivated for its vibrant crimson flowers, the plant also holds considerable ethnomedicinal value. Traditionally, various parts of *Calliandra haematocephala* have been used in the treatment of inflammatory disorders, epilepsy, fever, bacterial infections, and as a natural blood purifier. Tribal and folk communities (Ogbomoso, Oyo State) in Nigeria have employed its extracts for their anti-inflammatory, anticonvulsant, immunomodulatory, and antibacterial properties. Ethnomedicinal review revealed that this *Calliandra haematocephala* used for China, Jinjiang, Yunnan people leaf, flower and bark used by tranquilizing effect. A study was undertaken to investigate Antiepileptic and *In vitro* Antioxidant activities of *Calliandra haematocephala*.

**Materials and methods:** Leaves were collected from the Alagarkoil foot Hills, Madurai district, Tamil Nadu in the month of March 2025. It was authenticated by Dr. Stephen, Professor of Botany, The American College, Madurai-625002. Collected leaves were washed with water, shade dried powdered and aqueous extract were prepared. The extract was concentrated and stored in airtight container for further use.


These compounds are believed to contribute to its therapeutic potential. In the present study, fresh leaves of *Calliandra haematocephala* were collected, cleaned and crushed to juice using blender, the resulting juice was used for further analysis.

**Results and discussion:** The present study was evaluated for the pharmacological studies of Antioxidant and Anti epileptic activities of *Calliandra haematocephala* leaves using Zebrafish Model in comparison with standard for two activities.

**Keywords:** *Calliandra haematocephala*, Fabaceae, Evaluation of anti-epileptic activity and *Invitro* Anti-oxidant Assay

### Introduction

#### Graphical abstract



*Calliandra haematocephala*, belongs to Fabaceae, is an ornamental shrub commonly known as Red Powder Puff plant. It is native to Bolivia, but widely cultivated in India [1]. In Southern India the plant traditionally used to treat

pain, inflammatory conditions, and neurological disorders [2], In Tamil Nadu (Kani, Paliyar) [3] leaf and flower preparations for used to treat skin infections, wounds, fever and inflammatory disorders. In some parts of northeastern

India (Iruka, Kurumba) indigenous users rely on aqueous leaf extracts for gastrointestinal issues and as a general tonic [4]. In Central and South America, Nigeria, Colombia people used leaf decoction to treat diabetics and Yoruba, Nupe people used to treat malaria [5, 6]. In south western Nigeria Tude people used antioxidant and blood purifier [7]. In China, Jinjiang, Yunnan people leaf, flower and bark used by tranquilizing effect [8]. Phytochemical survey revealed the presence of flavanoids, terpenoids, saponins, phenolic compounds, glycosides and alkaloids [9]. It exhibited pharmacological activities such as, antimicrobial [10], antioxidant and anti-inflammatory [11], antidiabetic [12], hepatoprotective [13]. The objective of the study is to evaluate the pharmacognostical, physiochemical parameters, qualitative and quantitative estimation of *Calliandra haematocephala* leaves. An investigation was studied to identify the Antiepileptic activity of *Calliandra haematocephala* using Zebra fish model.

### Materials and methods

#### Preparation of aqueous extract of *Calliandra haematocephala* (AECHL)

The fresh, matured leaves of *Calliandra haematocephala* were collected, carefully washed with water, and shade-dried. The dried leaves were then ground into a fine powder. Approximately 20 g of the powdered material was boiled with 200 ml of water for 2 hours. The extract was subsequently filtered and concentrated to dryness. Separate batches were prepared as required for the study.

#### Preparation of fresh juice of *Calliandra haematocephala* leaves (*C. haematocephala*frj)

Fresh leaves of 20g were weighed, washed with water and 20ml of water is added to make a 20 ml of *Calliandra haematocephala* fresh juice.

#### Evaluation of Antiepileptic activities of *Calliandra haematocephala* Leaves

##### Experimental Animal

Adult zebrafish (*Danio rerio*) of both sexes, measuring approximately 3–4 cm in length and weighing 0.5–1.0 g,

were obtained from a certified aquaculture supplier. The fish were housed in 10-liter glass aquaria with continuous aeration and maintained at a temperature of  $27 \pm 1^\circ\text{C}$  under a controlled 14-hour light and 10-hour dark photoperiod. They were fed a commercial zebrafish diet twice daily. Before experimentation, the fish were acclimatized to laboratory conditions for seven days to minimize environmental stress and to ensure physiological stabilization (Lawrence, 2007) [14].

### 1. Acute toxicity study

#### Procedure

In the acute toxicity study, adult zebrafish were exposed to the aqueous extract of *Calliandra haematocephala* at concentrations of 50 mg/L and 100 mg/L for 24 hours in accordance with OECD (2013) guidelines [15]. Each group consisted of 10 males and 10 females (total 20 fish per group), and a separate control group was maintained without treatment. After 24 hours of observation, no mortality was recorded in either the control group or the treated groups. All fish appeared normal, with no alterations in swimming behavior, loss of equilibrium, or respiratory distress. No external lesions or abnormal mucus secretion were observed. Since no mortality occurred even at the highest concentration tested (100 mg/L), the median lethal concentration ( $\text{LC}_{50}$ ) could not be determined, and the 24-hour  $\text{LC}_{50}$  value was therefore considered to be greater than 100 mg/L under the present test conditions. The results were obtained in Fig.1 and Table.1.

Sex determination in zebrafish (*Danio rerio*). Image of male and female zebrafish and characteristics used to determine sex. Males have a longer and thinner tubular body shape and are darker in colour with a more yellow anal fin. Females have a rounder body shape and a silver belly.

#### Experimental design

The zebrafish were randomly divided into fourteen groups, each consisting of five animals ( $n = 5$ ). The dose range was selected based on preliminary dose-finding and pilot studies as well as previously reported literature on zebrafish models of epilepsy (Stewart *et al.*, 2014) [16].



**Fig 1:** Acute toxicity study of Zebra fish




Fig 2: Male and Female Zebra fish



Fig 3: Inducing group of Zebra fish



Fig 2: After treatment of male and female Zebra fish



**Drugs used**

**Inducing agent:** Pentylene tetrazole (PTZ),

**Standard drug:** Phenobarbitone-4mg/ml

**Test sample**

Aqueous extract of *Calliandra haematocephala* leaves (AECH<sub>L</sub>)

**Induction of Seizures**

Seizures were chemically induced using pentylene tetrazole (PTZ), a GABA-A receptor antagonist commonly used to model epileptic seizures in zebrafish.

A 15 mM solution of PTZ was freshly prepared in aquarium water and used as an immersion medium.

After treatment with the test extract or standard drug for 30 minutes, zebrafish were transferred to the pentylene tetrazole-containing tank for 20 minutes to induce seizures. This method has been widely validated for simulating epileptic phenotypes in zebrafish and allows for non-invasive, reproducible seizure induction (Baraban *et al.*, 2005) [17].

**Treatment Protocol Using Bath Immersion**

The test groups were treated using the bath immersion method, a standard route of drug administration in aquatic models. Zebrafish were immersed individually in tanks containing the respective concentrations of plant extract or phenobarbitone for 30 minutes. This was followed by immediate transfer to the pentylene tetrazole immersion tank. Control animals were immersed in the vehicle solution only. The bath immersion approach ensures systemic absorption of the compound via gills and skin, providing

effective systemic exposure without invasive procedures (Afrikanova *et al.*, 2013) [18]. The results were obtained in Table 2 & Fig.4,5,6.

**Evaluation of Parameters**

**Behavioral Seizure Assessment**

Post pentylene tetrazole exposure, each fish was individually observed for 20 minutes to assess seizure-like behaviour. Seizure activity was scored using a previously validated behavioural scoring scale

- 0 – no response
- 1 – short swim burst
- 2 – rapid swim with whirlpool behaviour
- 3 – clonic seizure with abnormal posture
- 4 – tonic seizure with loss of posture.

Additionally, the onset latency (time from pentylene tetrazole exposure to the first seizure), seizure duration, and frequency were recorded manually by a trained observer in a blinded manner. This behavioral scoring system has been widely employed to quantify seizure severity in zebrafish models (Kalueff *et al.*, 2014) [19].

**Procedure**

Adult zebrafish (*Danio rerio*), comprising equal numbers of males and females, were acclimatized in laboratory conditions for seven days prior to the experiment. Healthy and active fish of uniform size and weight were selected and maintained in aerated aquaria with controlled water quality parameters (temperature 26 ± 2 °C, pH 6.8–7.5, dissolved oxygen > 5 mg/L, photo period 14 h light/10 h dark). Fish

were not fed 24 hours before experimentation to avoid interference with drug absorption and metabolism.

The antiepileptic activity of the aqueous extract of *Calliandra haematocephala* leaves was evaluated using phenobarbitone sodium 0.04µg/ml (PBN) as the standard reference drug.

The test was performed according to OECD (2013) guidelines with minor modifications for zebra fish. Groups of fish (10 males and 10 females per group) were exposed to different concentrations of the aqueous extract (50 mg/L to 1.5 g/L), while one group received PBN (0.04µg/L) as standard and another group served as control.

**Table 1:** Anti-epileptic activity of Zebra fish experimental design

Group	Treatment	Dose	Route of Administration	Number of Animals (n)	
				Male	Female
Group I	Pentylene tetrazole (PTZ)	15mM	Immersion	5	5
Group II	Standard (Phenobarbitone) + 15 mM PTZ	0.04µg/L	Immersion	5	5
Group III	AECH <sub>L</sub> + 15 mM PTZ	50mg/L	Immersion	5	5
Group IV	AECH <sub>L</sub> + 15 mM PTZ	100mg/L	Immersion	5	5
Group V	AECH <sub>L</sub> + 15 mM PTZ	200mg/L	Immersion	5	5
Group VI	AECH <sub>L</sub> + 15 mM PTZ	400mg/L	Immersion	5	5
Group VII	AECH <sub>L</sub> + 15 mM PTZ	500mg/L	Immersion	5	5
Group VIII	AECH <sub>L</sub> + 15mM PTZ	600mg/l	Immersion	5	5
Group IX	AECH <sub>L</sub> + 15 mM PTZ	700mg/L	Immersion	5	5
Group X	AECH <sub>L</sub> + 15 mM PTZ	800mg/L	Immersion	5	5
Group XI	AECH <sub>L</sub> + 15 mM PTZ	900mg/L	Immersion	5	5
Group XII	AECH <sub>L</sub> + 15 mM PTZ	1g/L	Immersion	5	5
Group XIII	AECH <sub>L</sub> + 15 mM PTZ	1.25g/L	Immersion	5	5
Group XIV	AECH <sub>L</sub> + 15 mM PTZ	1.5g/L	Immersion	5	5

Each group of fish was transferred into glass aquarium containing the prepared test solution. After exposure, the onset of loss of equilibrium and immobility was monitored, and the duration of sedation was recorded. Fish were then placed in fresh water to recover, and the recovery time (defined as the interval between transfer to fresh water and regaining of normal swimming behaviour with equilibrium) was noted separately for males and females. Observations were made for all concentrations up to 1.5 g/L.

The behavioral parameters were expressed as recovery time (in minutes) for each group. A comparison was made between the PBN standard group and the plant extract groups to assess the concentration-dependent effect of the extract on zebra fish behaviour.

#### Locomotor data

Adult zebra fish (*Danio rerio*), aged 3–6 months, of both sexes (five males and five females in each group, n = 10) were procured and acclimatized in laboratory aquaria under standard husbandry conditions (26–28 °C, pH 7.0 ± 0.2, conductivity 400–450 µS, with a 14:10 h light–dark cycle). Fish were fed twice daily with commercial feed, and water was renewed on alternate days. All experimental protocols were approved by the Institutional Animal Ethics Committee (IAEC), following CPCSEA guidelines. Ethical committee clearance certifies that the project proposal no:11/2025 for 50 numbers of Zebra fish.

#### Experimental Procedure

Each fish was individually transferred to a transparent experimental tank (37x19cm), filled with 3–4 cm depth system water) and allowed to acclimate for 5 min. Baseline locomotor activity was recorded for 1 minute using an overhead digital video were analyzed using ToxTrac Software. Fish in the treatment groups were pre-exposed by immersion in the assigned concentration of the aqueous extract for 30 min. Following pretreatment, the fish were transferred to the test tank containing 15 mM PTZ solution,

and locomotor activity was recorded for 1 minute. Parameters measured included Average velocity (cm/sec), Average total distance moved (cm). Data were expressed as mean ± SEM. Statistical analysis was performed using one-way ANOVA followed by Bonferroni test was applied using Graph pad prism.

#### *In vitro* Antioxidant Assay

##### Determination of DPPH free radical scavenging assay

The effect of *C. haematocephala*frj on DPPH radical was estimated using the method of LiyanaPathiranan *et al.* (2005) [20]. About 0.1 ml of DPPH-methanol solution (0.135 mM) was mixed with 1.0 ml of different concentrations of sample. The reaction mixture was vortexed thoroughly and left in the dark at room temperature for 30 min. The absorbance of the mixture was measured spectrophotometrically at 517 nm. Vitamin C was used as standard drug. The results are obtained in Tab 5 & Fig 7. The percentage of free radical scavenging was calculated according to the following equation

$$\% \text{scavenging} = 100 - \frac{(\text{Abs sample} - \text{Abs blank})}{\text{Abs Control}} \times 100.$$

##### Determination of Hydrogen peroxide scavenging assay

Hydrogen peroxide scavenging assay was determined according to the method of (Rana MG 1996) [21] Various concentrations are prepared. 1ml of *C. haematocephala*frj were added to 2 ml of hydrogen peroxide solution (10 mM) in phosphate buffer (50 mM, pH 7.4). The extract was replaced by methanol for control. Reaction mixture was incubated at room temperature for 30 min. The unreacted hydrogen peroxide was determined by measuring the absorbance of the reaction mixture at 230 nm with respect to the blank (methanol) using UV/visible spectrophotometer.

The percentage inhibition was calculated according to the following equation. The results are obtained in Tab 6 & Fig 8.

$$\text{Percentage inhibition (\%)} = \frac{\text{Abs control} - \text{Abs sample}}{\text{Abs control}} \times 100$$

IC<sub>50</sub> values were estimated graphically using a non-linear regression algorithm

#### Determination of nitric oxide radical scavenging activity

Nitric oxide was generated from sodium nitroprusside and its scavenging effect was determined as per Green *et al.*, 1982; Morocci *et al.*, 1994 [22]. Different concentration of *C. haematocephala* in phosphate buffer was incubated with sodium nitroprusside for 5 hours at 25°C. Control experiments were performed with equal amount of buffer instead of solution. After 5 hours of incubation, 0.5ml of supernatant liquid was removed and 0.5ml of Griess reagent was added. The absorbance of the chromophore formed during diazotization with sulphanilamide and its subsequent coupling was read at 546nm. Vitamin C was used as standard and the nitric oxide scavenging was expressed in terms of ascorbic acid equivalents [23] and its results are presented in Tab 7 & Fig 9

#### Determination of ferric reducing antioxidant power (FRAP) activity

Ferric reducing antioxidant power activity was determined according to the method of Maruthamuthu Vijayalakshmi (2016) [24]. Different concentrations of *C. haematocephala* and its various fractions was added to 2.5ml of 0.2M sodium phosphate buffer (PH 6.6) and 2.5ml of 1% potassium ferricyanide solution. The reaction mixture was vortexed well and then incubated at 50°C for 20min using vortex shaker. At the end of the incubation, 2.5ml of 10% trichloroacetic acid was added to the mixture and centrifuged at 3000rpm for 10 min. The supernatant (2.5ml) was mixed with 2.5ml of deionized water and 0.5ml of 0.1% ferric chloride. The colored solution was read at 700nm against the blank with reference to standard using UV-Spectrophotometer. Vitamin C was used as standard. The results are presented in Tab 8 & Fig 10

#### Determination of total antioxidant capacity content

Total antioxidant capacity was determined according to the method of Prieto P (1999) [25]. *C. haematocephala* in different concentrations were prepared individually containing 3ml of distilled water and 1ml of Molybdate reagent solution. These tubes were kept incubated at 95°C for 90min. After incubation, these tubes were normalized to room temperature for 20-30 min and the absorbance of the reaction mixture was measured at 695nm. Mean values from three independent samples were calculated for each *C. haematocephala*. Vitamin C was used as standard. The results were displayed in Tab 9 & Fig 11

## Results and Discussion

### Behavior Assessment

These findings demonstrate that the aqueous extract exerts a concentration-dependent effect on behavioral recovery, with a significant reduction in recovery time observed at concentrations above 400 mg/L. The results suggest possible central nervous system (CNS) activity of the extract, which may be attributed to its phytoconstituents such as flavonoids, Pyrolidine alkaloids, saponins. Flavonoids in particular are known to interact with the GABAergic system and modulate sedative and anticonvulsant activity. Flavonoids in particular are known to interact with the GABAergic system and modulate sedative and anticonvulsant activity, Pyrolidine alkaloids of Succinamide acts as, a Neuroprotective potential while antioxidant compounds may enhance neuronal stability and recovery. Interestingly, female zebrafish generally recovered faster than males at higher concentrations, suggesting potential sex-related differences in metabolism or sensitivity to the bioactive compounds.

When compared to phenobarbitone (0.04µg/ml), which produced stable recovery times, the extract at higher concentrations demonstrated enhanced recovery, implying either potentiation of neuronal excitability or an independent mechanism distinct from phenobarbitone's sedative action.

### Locomotor activity

The present study demonstrated that the aqueous leaf extract of *Calliandra haematocephala* exerted significant protective effects against PTZ-induced locomotor hyperactivity in zebrafish. PTZ, a GABA-A receptor antagonist, is well known to induce seizure-like phenotypes in zebrafish, manifested as increased velocity and total distance moved (Baraban *et al.*, 2005). In the current assay, PTZ produced a robust increase in locomotor activity, consistent with seizure induction.

Pretreatment with the plant extract attenuated the PTZ-induced hyperactivity in a dose-dependent manner. At higher concentrations (≥ 900 mg/L), locomotor activity was significantly reduced, approaching baseline control values. This indicates that the extract may possess anticonvulsant activity by counteracting PTZ-induced excitability.

The protective effect could be attributed to the phytoconstituents of *Calliandra haematocephala*, including flavonoids, saponins, and alkaloids, which have been reported to modulate the GABAergic system and exhibit antioxidant properties (Joseph and Mathew, 2021; Kumar *et al.*, 2019). Antioxidant mechanisms are particularly relevant, as oxidative stress is implicated in seizure pathophysiology.


At lower concentrations (50–200 mg/L), the extract failed to significantly suppress PTZ-induced hyperlocomotion, suggesting that a threshold concentration is required to elicit anticonvulsant effects. This dose-dependent trend highlights the pharmacological potential of the plant extract and supports its traditional ethnomedicinal use in neurological disorders.

**Table 2:** Assessment of Behavior and Locomotor parameters against Pentylene tetrazole induced epilepsy in Zebra fish model


S.No.	Group	Behavior		Velocity (cm/sec)		Total distance moved (cm/sec)	
		Male	Female	Male	Female	Male	Female
1	PTZ	-	-	0.92±0.032	0.88±0.0418	55.2±1.972	53±2.5111
2	PBN	30±4.41	20±8.81	0.72±0.0311*	0.71±0.0233	43.2±2.391**	42.4±1.390
3	50mg/L	45±4.41	45±8.81	0.81±0.081	0.81±0.0806	54±2.415	60±3.726
4	100mg/L	45±4.41	45±8.81	0.81±0.081	0.81±0.0806	55.4±3.844	58±2.0206
5	200mg/L	40±6.00	40±4.40	0.8±0.062	0.83±0.0878	48±3.726	50±5.270
6	400mg/L	30±4.40	30±4.40	0.83±0.0121	0.82±0.0254	49.8±0.726	48.8±1.527
7	500mg/L	30±7.21	25±6.23	0.74±0.052	0.78±0.0499	47.4±3.162	46.6±2.995
8	600mg/L	25±4.41	20±6	0.85±0.0549	0.77±0.0447	51±3.543	46.4±2.688
9	700mg/L	25±6	30±4.41	0.85±0.371	0.74±0.0253	50.8±2.229	44.6±1.518
10	800mg/L	30±5.77	20±4.40	0.83±0.0227	0.75±0.0396	49.6±1.364	45.2±2.380
11	900mg/L	20±4.40	20±4.40	0.74±0.0394	0.7±0.0240*	44.6±2.374*	42±1.433*
12	1g/L	15±3.71	10±1.45	0.69±0.400**	0.67±0.0121**	41.8±2.403**	40±0.726**
13	1.25g/L	12±3.05	6±1.45	0.63±0.0346***	0.66±0.0198**	37.8±2.081****	39.6±1.190**
14	1.5g/L	8±1.76	5±0.88	0.61±0.044****	0.64±0.0371**	36.6±2.645****	38.4±2.229***

In the PTZ-induced zebrafish epilepsy model, the aqueous leaf extract of *Calliandra haematocephala* exhibited a clear dose-dependent anticonvulsant effect. Behavioural scores in both male and female zebrafish showed no significant differences between the disease, treatment, and standard groups ( $p > 0.05$ ), indicating that the extract did not alter behavioural seizure scoring under these conditions. In contrast, locomotor parameters demonstrated marked improvements. In male zebrafish, velocity was significantly reduced at 1 g ( $p = 0.0036^{**}$ ), 1.25 g ( $p = 0.0002^{***}$ ), and 1.5 g ( $p < 0.0001^{****}$ ), while total distance moved decreased significantly at 900 mg ( $p = 0.0329^*$ ), 1 g ( $p =$

$0.0011^{**}$ ), 1.25 g ( $p < 0.0001^{****}$ ), and 1.5 g ( $p < 0.0001^{****}$ ). The standard drug also showed significant protection versus disease ( $p = 0.0414^*$  for velocity;  $p = 0.0063^{**}$  for distance). In female zebrafish, velocity was significantly reduced at 900 mg ( $p = 0.0364^*$ ), 1 g ( $p = 0.0078^{**}$ ), 1.25 g ( $p = 0.004^{**}$ ), and 1.5 g ( $p = 0.0012^{**}$ ), while total distance moved was significantly reduced at 900 mg ( $p = 0.0375^*$ ), 1 g ( $p = 0.003^{**}$ ), 1.25 g ( $p = 0.0018^{**}$ ), and 1.5 g ( $p = 0.0004^{****}$ ). Comparisons of the standard drug with lower doses (50 mg, 100 mg) also revealed highly significant differences ( $p < 0.0001^{****}$ ).



**Fig 4:** Behavior assessment of male [A] and female [B] Zebra fish



**Fig 5:** Total Distance moved of male [C] and female [D]




Fig 6: Velocity of male [E] and female [F]

**In vitro anti-oxidant assay**

In vitro anti-oxidant activity of *C. haematocephalafrj* were determined by five methods and the results are depicted below

**DPPH free radical scavenging assay**

Various concentrations (0 to 10 µg/ml) of *C. haematocephalafrj* were treated with DPPH and the absorbance was observed and displayed in Tab 3&Fig 7

Table 3: Determination of DPPH free radical scavenging assay of *C. haematocephalafrj*

S.No.	Concentration (µg/ml)	Percentage of inhibition	
		<i>C.haematocephalafrj</i>	Ascorbicacid
1	0	0	0
2	2	17.57	29.92
3	4	34.14	37
4	6	39.46	43.83
5	8	43.2	50.09
6	10	49.79	55.28
	IC <sub>50</sub>	9.081	7.846




Fig 7: Graphical data of DPPH free radical scavenging assay of *C. haematocephalafrj*


The inhibitory concentration IC<sub>50</sub> value of *C. haematocephalafrj* was found to be 9.08µg/ml in comparison with ascorbic acid as standard 7.85 µg/ml

**Hydrogen peroxide scavenging assay**

Various concentrations (0 to10 µg/ml) of *C. haaematocephalafrj* were treated with hydrogen peroxide and the absorbance was observed and displayed in Tab 6 & Fig 8.

Table 4: Determination of Hydrogen peroxide scavenging assay of *C. haematocephalafrj*

S.No.	Concentration (µg/ml)	Percentage of inhibition	
		<i>C.haematocephalafrj</i>	Ascorbicacid
1	0	0	0
2	2	22.1	29.93
3	4	30.46	55.03
4	6	48.47	62.23
5	8	51.95	72.09
6	10	76.73	95.26
	IC <sub>50</sub>	6.669	4.721



**Fig 8:** Graphical data of Hydrogen peroxide scavenging assay of *C. haematocephala*frj


The inhibitory concentration IC<sub>50</sub> value of *C. haematocephala*frj was found to be 6.67µg/ml in comparison with ascorbic acid as standard 4.72µg/ml

**Nitric oxide scavenging assay**

Various concentrations (0 to 25 µg/ml) of *C. haematocephala*frj were treated with griess reagent and the absorbance was observed and displayed in Tab 5 & Fig 9.

**Table 5:** Determination of Nitric oxide scavenging assay of *C. haematocephala*frj

S.No.	Concentration (µg/ml)	Percentage of inhibition	
		<i>C. haematocephala</i> frj	Ascorbic acid
1	0	0	0
2	5	18.67	27.25
3	10	27.28	32.03
4	15	32.07	38.4
5	20	32.64	44.24
6	25	33.24	50.08
	IC <sub>50</sub>	13.55	9.09



**Fig 9:** Graphical data of Nitric oxide scavenging assay of *C. haematocephala*frj


The inhibitory concentration IC<sub>50</sub> value of *C. haematocephala*frj was found to be 13.55µg/ml in comparison with ascorbic acid as standard 9.09µg/ml

**Ferric reducing anti-oxidant power (FRAP) activity**

Various concentrations (0 to 10 µg/ml) of *C. haematocephala*frj were treated with potassium ferricyanide and the absorbance was observed and displayed in Tab 6 & Fig 10.

**Table 6:** Determination of ferric reducing anti-oxidant power (FRAP) activity of *C. haematocephala*frj

S.No.	Concentration (µg/ml)	Percentage of inhibition	
		<i>C. haematocephala</i> frj	Ascorbic acid
1	0	0	0
2	2	19.56	31.1
3	4	22.5	37.29
4	6	25.49	43.32
5	8	28.04	47.23
6	10	31.43	53.42
	IC <sub>50</sub>	15.87	8.18



**Fig 10:** Graphical data of ferric reducing antioxidant power (FRAP) activity of *C. haematocephala*


The inhibitory concentration IC<sub>50</sub> value of *C. haematocephala* was found to be 15.87 µg/ml in comparison with ascorbic acid as standard 8.18 µg/ml

Various concentrations (0 to 10 µg/ml) of *C. haematocephala* were treated with molybdate reagent and the absorbance was observed and displayed in Tab 7 & Fig 11.

**Total antioxidant capacity**

**Table 7:** Determination of total anti-oxidant capacity of *C. haematocephala*

S.No.	Concentration (µg/ml)	Percentage of inhibition	
		<i>C. haematocephala</i>	Ascorbic acid
1	0	0	0
2	2	24.57	28.23
3	4	28.54	36.47
4	6	34.75	53.23
5	8	38.36	73.67
6	10	42.12	91.17
	IC <sub>50</sub>	10.94	5.33



**Fig 11:** Graphical data of total antioxidant capacity of *C. haematocephala*

The inhibitory concentration IC<sub>50</sub> value of *C. haematocephala* was found to be 10.94 µg/ml in comparison with ascorbic acid as standard 5.33 µg/ml

### Conclusion

The present investigation demonstrates that the leaf extract of *Calliandra haematocephala* possesses significant antiepileptic activity in zebra fish model. These results provide preliminary evidence supporting the ethnopharmacological claims of *Calliandra haematocephala* in neurological disorders, particularly in relation to its antiepileptic and neuroprotective potential. However, further studies involving biochemical assays, receptor binding, and histopathological analysis are necessary to establish the precise mechanism of action and confirm the safety and efficacy of the extract.

### Acknowledgement

I would like to express my sincere gratitude to our principal, Dr. T. Venkata Rathina Kumar, for providing me the facilities to conduct this research.

### References

- Rao KS, Sreeramulu K. Phytochemical and pharmacological potential of *Calliandra haematocephala* – A review. *International Journal of Pharmacognosy and Phytochemical Research*,2017;9(5):658–662.
- Pushpangadan P, Atal CK. Ethnomedico-botanical investigations in Kerala: Some primitive tribes of Western Ghats and their herbal medicine. *Journal of Ethnopharmacology*,1984;11(1):59–77.
- Vedavathy S, Rao KN, Narasimha BL. Ethnobotany of Eastern Ghats in Andhra Pradesh, India. *Economic Botany*,1997;51(4):305–312.
- Devi YS, Singh PK. Ethnobotanical uses of medicinal plants in Manipur Valley. *Indian Journal of Traditional Knowledge*,2013;12(3):434–442.
- Akinmoladun FO, Akinrinlola BL, Komolafe AO. Ethnomedicinal uses and pharmacological potential of *Calliandra* species in Africa. *Journal of Herbal Medicine*,2018;14:100226.
- Gbolade AA. Ethnobotanical study of plants used in treating malaria in southwestern Nigeria. *African Journal of Traditional, Complementary and Alternative Medicines*,2009;6(3):287–293.
- Ogudemi, T. *Outlines and Pictures of Medicinal Plants from Nigeria*. 1st ed. Lagos: University of Lagos Press, 2006, 95–156.
- Zhang Q, Wang Y, Yang L. Ethnobotanical survey of medicinal plants used by Yunnan ethnic groups. *Journal of Ethnopharmacology*,2012;140(3):606–618.
- Mahesh S, Satish S. Antimicrobial activity of some important medicinal plants against plant and human pathogens. *World Journal of Agricultural Sciences*,2008;4(5):839–843.
- Ríos JL, Recio MC. Medicinal plants and antimicrobial activity. *Journal of Ethnopharmacology*,2005;100(1–2):80–84.
- Eze SO, *et al.* Antioxidant and anti-inflammatory activities of plant extracts in traditional medicine. *Phytotherapy Research*,2019;33(6):1568–1578.
- Punnagai K, *et al.* Alpha amylase and alpha glucosidase inhibitory effects of *Calliandra haematocephala*. *Asian Journal of Pharmaceutical and Clinical Research*,2018;11(12):429.
- Pereira DF, *et al.* Phytochemical and pharmacological investigations of *Calliandra* species. *Natural Product Research*,2010;24(9):842–849.
- Lawrence C. The husbandry of zebrafish (*Danio rerio*): A review. *Aquaculture*,2007;269(1-4):1-20. <https://doi.org/10.1016/j.aquaculture.2007.04.046>
- OECD "OECD Guideline for the Testing of Chemicals, Test No. 236: Fish Embryo Toxicity (FET) Test." Organization for Economic Co-operation and Development, 2013.
- Stewart A, Tanguay RL, McCarthy M. Zebrafish models of epilepsy and seizures: Applications for drug discovery. In: Reggio, P.H. (Ed.), *Pharmacology of Neurologic Disorders* Springer, 2014, 201-213.
- Baraban SC, Dinday MT, Hortopan GA. Drug screening in the zebrafish seizure model. *Progress in Brain Research*,2005;161:277-284. [https://doi.org/10.1016/S0079-6123\(06\)61021-3](https://doi.org/10.1016/S0079-6123(06)61021-3)
- Afrikanova T, Gonzalez L, Radisic M. Methods for drug administration in zebrafish. *Journal of Drug Delivery Science and Technology*,2013;23(5):459-467. <https://doi.org/10.1016/j.jddst.2013.05.005>
- Kalueff AV, Stewart AM. Zebrafish models of neurodevelopmental disorders. In: Kalueff, A.V., & Stewart, A.M. (Eds.), *Neurodevelopmental Disorders in Children* Springer, 2014, 55-71.
- Liyana-Pathiranan S, Shahidi F. Antibacterial and Antioxidant Activities of *Adiantum Pedatum* L. *Journal of Phytology*,2005;31:26-32.
- Rana MG, Katbamna RV, Padhya AA, Dudhrejiya AD, Jivani NP, Sheth NR *in vitro* antioxidant and free-radical scavenging studies of alcoholic extract of *Medicago sativa* L. *Rom J Biol – Plant Biol*,1996;55(1):15–22.
- Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenabnum SR.1 Analysis of nitrate and 15N in biological fluids. *Anal.Biochem*,1982;126:1 31.
- Morocci L, Maguirre JJ, Droy-Lefaix MT, Packer L. The nitric oxide scavenging properties of *Ginkgo biloba* extract EGb761. *Biochem. Biophys. Res. Commun*,199 4:201:748-755.
- Maruthamuthu Vijayalakshmi, Kandasamy Ruckmani. Ferric reducing antioxidant power assay in plant extract. *Bangladesh J Pharmacol*,2016;11:570-572.
- Prieto P, Pineada M, Aguilar M. Spectrophotometric quantification of antioxidant capacity through the formation of a phosphomolybdenum complex: specific application to the determination of vitamin E. *Anal Biochem*,1999;269:237-241.